Clinical Trial Update: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describes EO2463, a novel vaccine, being studied as monotherapy and in combination for indolent non-Hodgkin lymphoma. The trial targets …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• EO2463

Snippet

Sponsor: Enterome | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1, Phase 2 | Status: RECRUITING